Subscribe to our Newsletters !!
In molecular biology, the LAMP (Loop-Mediated Isot
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
In a world constantly in motion, Microbioz India r
New Delhi, Nov 12 (PTI) Drug firm Lupin on Thursday stated that in alliance with Concord Biotech, it has obtained acceptance from the US health regulator to market generic immunosuppressant Tacrolimus capsules used in the Western industry. In cooperation with Concord Biotech, the business has obtained approval from the United States Food and Drug Administration (USFDA) to advertise Tacrolimus capsules USP, at the advantages of 0.5 mg, 1 mg, and 5 milligrams, Lupin said in a filing to the BSE.
The product is a standard version of Astellas Pharma US, Inc”s Prograf capsules at exactly the very same strengths, it added.
According to IQVIA MAT September 2020 data, Tacrolimus capsules USP (0.5 mg, 1 mg, and 5 mg) had an yearly sales of about USD 303 million at the united states, Lupin explained.
The capsules are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, heart or kidney transplant, in conjunction with other immunosuppressants, it included.
Shares of Lupin Ltd on Thursday dropped 1.76 percent to Rs 897.70 per scrip on t
he BSE. PTI AKT HRS
